Literature DB >> 10051112

Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.

L S Kegeles1, Y Zea-Ponce, A Abi-Dargham, J Rodenhiser, T Wang, R Weiss, R L Van Heertum, J J Mann, M Laruelle.   

Abstract

Binding competition between endogenous dopamine (DA) and the D2 receptor radiotracer [123I]IBZM allows measurement of the change in synaptic DA following amphetamine challenge with SPECT in the living human brain. Previous investigations using this technique in healthy subjects have shown that the magnitude of amphetamine effect on [123I]IBZM binding potential (BP) is small (range between 5 to 15% decrease), and that a large between-subject variability in this effect is observed. Therefore, it was unclear how much of the apparent between-subject variability was due to a low signal-to-noise ratio in the measurement, vs. true between-subject differences in the magnitude of the response. The goals of this investigation were to test the within-subject reproducibility and reliability of amphetamine-induced decrease in [123I]IBZM BP with a test/retest paradigm, and to establish the presence or absence of tolerance or sensitization to single administration ofi.v. amphetamine. Six healthy male subjects, never previously exposed to psychostimulants, twice underwent measurement of striatal amphetamine-induced DA release (between-measurement interval 16 +/- 10 days) using SPECT and the [123I]IBZM constant infusion technique. Results demonstrated an excellent within-subject reproducibility of amphetamine-induced DA release: amphetamine-induced decreases in [123I]IBZM BP were significant on each day, and had an intraclass correlation coefficient (ICC) of 0.89. Moreover, values from the second experiment were not significantly different from first experiment, suggesting the absence of either sensitization or tolerance to the effect of amphetamine on DA release in these experimental conditions. The subjective activation, as rated by the subjects on analog scales, was also highly reproducible. In conclusion, this scanning technique provides a reliable measurement of amphetamine-induced reduction of [123I]IBZM BP and enables detection of between-subject differences that appear stable over time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051112     DOI: 10.1002/(SICI)1098-2396(19990315)31:4<302::AID-SYN9>3.0.CO;2-A

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  18 in total

1.  Dopaminergic system dysfunction in recreational dexamphetamine users.

Authors:  Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 3.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

4.  Stability of acute responses to drugs in humans across repeated testing: Findings with alcohol and amphetamine.

Authors:  Conor H Murray; Jessica Weafer; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

Review 5.  Cocaine sensitization and dopamine mediation of cue effects in rodents, monkeys, and humans: areas of agreement, disagreement, and implications for addiction.

Authors:  Charles W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  2006-10-10       Impact factor: 4.530

6.  Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.

Authors:  Paul Shotbolt; Andri C Tziortzi; Graham E Searle; Alessandro Colasanti; Jasper van der Aart; Sergio Abanades; Christophe Plisson; Sam R Miller; Mickael Huiban; John D Beaver; Roger N Gunn; Marc Laruelle; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

7.  Assessment of methylphenidate-induced changes in binding of continuously infused [(11)C]-raclopride in healthy human subjects: correlation with subjective effects.

Authors:  J I Udo de Haes; R Kortekaas; A Van Waarde; R P Maguire; J Pruim; J A den Boer
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

8.  Noninvasive visualization of human dopamine dynamics from PET images.

Authors:  E D Morris; C C Constantinescu; J M Sullivan; M D Normandin; L A Christopher
Journal:  Neuroimage       Date:  2010-01-04       Impact factor: 6.556

9.  Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.

Authors:  Alessandro Bertolino; Paolo Taurisano; Nicola Marco Pisciotta; Giuseppe Blasi; Leonardo Fazio; Raffaella Romano; Barbara Gelao; Luciana Lo Bianco; Madia Lozupone; Annabella Di Giorgio; Grazia Caforio; Fabio Sambataro; Artor Niccoli-Asabella; Audrey Papp; Gianluca Ursini; Lorenzo Sinibaldi; Teresa Popolizio; Wolfgang Sadee; Giuseppe Rubini
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

10.  Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis".

Authors:  Elisabet Aliagas; Izaskun Villar-Menéndez; Jean Sévigny; Mercedes Roca; Miriam Romeu; Isidre Ferrer; Mireia Martín-Satué; Marta Barrachina
Journal:  Purinergic Signal       Date:  2013-06-16       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.